Series Home | October 13 Webinar | Past Webinars | Webinar Video Archive | Registration





The Leading Forum on Healthcare Privacy, Confidentiality, Data Security & HIPAA Compliance

National Pharma Audioconferences



WEDNESDAY, JULY 29, 2020
Pharma/Device Compliance Webinar: Compliance During a Crisis Series: Session I: Have You Incorporated Tele-Compliance into Your Business Continuity Plans?



THURSDAY, JUNE 4, 2020
Pharma/Device Compliance Webinar: Response to COVID-19 Webinar Series: Part VI: Global Roundtable on Special Issues Raised by the COVID-19 Pandemic for Medical Device Ethics and Compliance Professionals and In-House Counsel



THURSDAY, MAY 14, 2020
Pharma/Device Compliance Webinar: Response to COVID-19 Webinar Series: Part V: Navigating Clinical Trials During the COVID-19 Pandemic



THURSDAY, APRIL 30, 2020
Pharma/Device Compliance Webinar: Response to COVID-19 Webinar Series: Part IV: Challenges Posed by Field, Commercial & Medical Personnel Change to Digital/Virtual Promotional Activities in Response to the COVID-19 Pandemic



THURSDAY, APRIL 23, 2020
Pharma/Device Compliance Webinar: Response to COVID-19 Webinar Series: Part III: US FCPA and Global Anticorruption Update for Pharma & Med Device



MONDAY, APRIL 13, 2020
Pharma/Device Compliance Webinar: Response to COVID-19 Webinar Series: Part II: Managing Pharma & Medical Device Ethics & Compliance Function Remotely



MONDAY, APRIL 6, 2020
Pharma/Device Compliance Webinar: Response to COVID-19 Webinar Series: Part I: COVID-19 Pandemic Action Plan for Pharma & Medical Device Ethics & Compliance Teams



THURSDAY, SEPTEMBER 15, 2016
Pharma Compliance Webinar: Phrma/Bio Joint Principles on Responsible Sharing of Truthful and Non-Misleading Information about Medicines with Health Care Professionals and Payers



TUESDAY, JUNE 7, 2016
Medical Affairs Compliance - Lessons Learned and Best Practices



WEDNESDAY, JANUARY 11, 2012
Analysis of the Proposed Sunshine Rule



MONDAY, DECEMBER 13, 2010
An Update on FCPA Enforcement in the Life Sciences Industry



THURSDAY, AUGUST 12, 2010
Examining the Latest Developments in Drug and Device CIAs How Corporate Integrity Agreements Continue to Reshape Compliance



WEDNESDAY, JUNE 16, 2010
Ten Emerging Risk Areas for Drug and Device Companies



TUESDAY, DECEMBER 1, 2009
Lessons of Pfizer's $2.3 Billion Off-Label Settlement



WEDNESDAY, DECEMBER 17, 2008
How State Attorneys General Are Reshaping Pharmaceutical Marketing and Compliance through Fraud Investigations and Settlements
Analysis of Eli Lilly's $62 Million Zyprexa Settlement and Pfizer's $895 million Bextra Settlement
A National Audioconference Sponsored by Harvard Health Policy Review and Rx Compliance Report



TUESDAY, DECEMBER 9, 2008
Advanced Implementation Strategies for a Compliant Grant Process



THURSDAY, DECEMBER 4, 2008
The Lessons of Cephalon's $425 Million Off-Label Settlement: A New Model for Off-label Enforcement



TUESDAY, AUGUST 5, 2008
Analyzing the Newly Revised PhRMA Code



TUESDAY, JUNE 17, 2008
Operating in an Uncertain Environment: The Impact of FDA's Draft Guidance on Medical Journal Reprints and Other Recent Developments



TUESDAY, MAY 27, 2008
Dealing with Transparency - How Drug and Device Companies are Operationalizing Disclosure of Educational Grants



WEDNESDAY, MARCH 26, 2008
Lessons from Merck's $671 Million Medicaid Drug Pricing Settlement



WEDNESDAY, JANUARY 9, 2008
Industry-Supported CME under Fire: Mitigating Risk and Enhancing Compliance



MONDAY, NOVEMBER 26, 2007
Lessons of BMS' $515 Million Settlement for Off-label Promotion, Kickbacks and Drug Pricing



WEDNESDAY, DECEMBER 13, 2006
The InterMune Off-label Settlement and the Rise of Deferred Prosecution Agreements



WEDNESDAY, NOVEMBER 29, 2006
How the Democratic Takeover of Congress will Impact Pharma



WEDNESDAY, MARCH 8, 2006
Compliance in a Highly Litigious World - Creating Good Documents and Avoiding Bad Ones



TUESDAY, DECEMBER 6, 2005
Global Compliance Systems: The Next Horizon for Pharma Compliance



THURSDAY, OCTOBER 27, 2005
Understanding the Inner Workings of FDA: - A Conversation With Peter Barton Hutt,"the Unofficial Dean of Washington Food and Drug Lawyers"



TUESDAY, SEPTEMBER 13, 2005
Overview and Implications of PhRMA's DTC Drug Marketing Guidelines



THURSDAY, JULY 28, 2005
Pharmaceutical Drug Pricing and Reporting Issues



WEDNESDAY, JUNE 8, 2005
Fraud and Abuse Issues for Medical Device Companies



MONDAY, MAY 2, 2005
The New California State Law and Other State Laws Targeting Pharmaceutical Sales and Marketing



MONDAY, APRIL 11, 2005
FDA's Final Risk Management Guidance: Improving Drug Safety Through RiskMAPs (Risk Minimization Action Plans)



TUESDAY, FEBRUARY 17, 2005
Update on the Medicare Drug Benefit and Medicare Advantage Regulations



THURSDAY, OCTOBER 26, 2004
The Expanding Scope of Fraud Investigations and Enforcement in Clinical Trials, Publication and Off Label Use



WEDNESDAY, JUNE 23, 2004
Lessons of the Pfizer Settlement for Off Label Promotion - Compliance Issues and Practices



TUESDAY, MAY 11, 2004
The Lessons of the Medco Settlement and Implications for PBM Regulation, Roles and Operations



TUESDAY, MARCH 23, 2004
Analysis of the FDA's Draft Guidance on Direct to Consumer (DTC) Advertising



TUESDAY, FEBRUARY 10, 2004
PBM Regulation, Investigation, Prosecution and Compliance



WEDNESDAY, JANUARY 28, 2004
The New Medicare-Endorsed Prescription Drug Discount Card Program: How it Will Work and Who Will Participate



WEDNESDAY, JANUARY 14, 2004
The Implications of the New Medicare Prescription Drug Legislation for Pharmaceutical Manufacturers, PBMs and Health Plans



THURSDAY, OCTOBER 16, 2003
The New Risk Area - Internal Investigations in a Post Sarbanes Oxley World



THURSDAY, OCTOBER 2, 2003
Off Label Promotion - Compliance Issues and Practices



THURSDAY, SEPTEMBER 18, 2003
Operationalizing the OIG Pharmaceutical Guidance - Grants, Consulting Agreements and Sales and Marketing



WEDNESDAY, MAY 21, 2003
An Analysis of the New OIG Model Compliance Guidance for the Pharmaceutical Industry



TUESDAY, OCTOBER 22, 2002
An Analysis of the New OIG Model Compliance Guidance for the Pharmaceutical Industry



TUESDAY, OCTOBER 8, 2002
The Implications of New Corporate Governance Rules on Compliance in the Pharmaceutical Industry



WEDNESDAY, MAY 29, 2002
HIPAA for Pharmaceutical Manufacturers, PBMs, and Pharmacies






Series Home | October 13 Webinar | Past Webinars | Webinar Video Archive | Registration




© Health Care Conference Administrators
Contact Webmaster